



Published in final edited form as:

MOJ Immunol. 2018 ; 6(2): 34–42.

Regulatory T Cells in Gynecologic Cancer

Yang Ou¹, Martin J. Cannon², and Mayumi Nakagawa^{1,*}

¹Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR USA

²Department of Microbiology and Immunology, University of Arkansas for Medical Sciences, Little Rock, AR USA

Abstract

Increasing evidence supports that regulatory T cells (Tregs) within the tumor, tumor draining lymph nodes, ascites and peripheral blood of patients with cancer are associated with poor prognosis. Tregs are important mediators of active immune evasion in cancer. In this review, the potential mechanisms of Treg actions and the roles of Tregs specifically in the tumor microenvironment derived from three types of gynecological cancers, cervical, vulvar and ovarian, are described. The correlations between Tregs and clinical immunotherapeutic study outcomes are discussed. Successful modulation of Tregs would likely have significant impact on the effectiveness of immunotherapeutic treatments in cancer patients.

Keywords

Tregs; cancer; cervical; vulvar; ovarian

1. Introduction

Understanding the role of the immune system in the control of cancer growth has been a field of intense investigation over the past decades. The advances in the knowledge of the immune system has led to the view of it as a dual role player in suppressing tumor growth and facilitating tumor progression. The studies in murine models identified tumors as sites of immune tolerance based on the observation that tumor-bearing mice have functional systemic T cell responses with *in vitro* and *in vivo* assays despite continued tumor growth (1, 2). The concept of T cell suppression was initially established in 1970s. The antigen-specific tolerance could be transferred with antigen-experienced T cells (3). A considerable body of research suggested the existence of *in vivo* mechanisms of tumor-driven cellular immune suppression (4–7). For example, complete regression of established tumors in a chemically induced fibrosarcoma mouse model, mediated by passively transferred sensitized T cells from immunized donors fail to occur unless the tumors were growing in

*Mayumi Nakagawa, University of Arkansas for Medical Sciences, 4301 West Markham Street, Slot 502, Little Rock, AR 72205, USA, Tel: (501) 686-8635; Fax: (501) 526-4621; mnakagawa@uams.edu.

Conflict of interest

Mayumi Nakagawa is named as one of the inventors of PepCan in patents and patent applications describing it. Martin Cannon and UAMS have a financial interest through licensed patents in aspects of the technology discussed in this publication. These financial interests have been reviewed and approved in accordance with the UAMS conflict of interest policies.

thymectomized T-cell-deficient recipients (6). Certain CD4 T cell clones selectively down-regulated the induction of cytotoxic anti-immune responses in a human melanoma model (7). In this paper, the functions of regulatory T cells (Tregs), one of the most important immunosuppressive mediators especially in studies of gynecological cancer, are reviewed.

2. Regulatory T cells (Tregs)

Tregs, as one of the principle cell types responsible for the induction of dominant immune tolerance to tumors, were first identified by Sakaguchi (8). The initial studies by his group demonstrated that elimination of CD25⁺CD4⁺ T cells elicited autoimmune disease in a murine model (8). Furthermore, removal of CD4⁺CD25⁺ T cells evoked tumor-specific immune responses to syngeneic tumors *in vivo* and eradicated them in mice (9). The research from Nakayama's group demonstrated that *in vivo* administration of anti-CD25 monoclonal antibody caused regression in six of eight murine tumors in syngeneic mice (10). Tregs are divided by lineage into thymic-derived regulatory T cells (tTregs) and peripheral regulatory T cells (pTregs) (Figure 1). tTregs are selected by high-avidity interaction with self-MHC class II-dependent T-cell receptors in the thymus (11, 12). pTregs are derived from naïve CD4⁺ T cells by sub-optimal antigen presentation in the periphery (13). tTregs specifically express the transcription factor forkhead box protein 3 (Foxp3), a "master regulator" of the suppressive lineage while pTregs are generated from Foxp3⁻ precursors (14). Once they are induced, pTregs begin to express Foxp3. It has been shown that expansion of tTregs and *de novo* generation of pTregs both independently contributed to tumor-specific T cell tolerance in a murine model (15). pTregs comprise two additional Foxp3⁻ subsets interleukin-10 producing Type 1 Tregs (Tr1) (16, 17) and transforming growth factor-β (TGF-β)-dependent T helper 3 cells (Th3) (Figure 1), which are most commonly associated with oral tolerance (18).

3. Tregs in Human Cancers

Accumulating evidence demonstrated an enrichment of CD4⁺CD25⁺ Tregs within the tumor mass, peripheral blood, tumor draining lymph nodes or ascites in cancer patients. For example, an increased percentage of CD4⁺CD25⁺ Tregs was observed in the non-small cell lung cancer tumor-infiltrating lymphocytes and ovarian cancer tumor-associated lymphocytes (19). Likewise, increased numbers of Tregs was reported in peripheral blood and tumor infiltrating lymphocytes of patients with hepatocellular carcinoma compared to controls including healthy donors and patients with liver disease but without liver malignancies (20). Significantly higher frequency of CD4⁺CD25⁺Foxp3⁺ Tregs in tumor infiltrating lymphocytes was demonstrated in early and advanced stage gastric cancer patients compared to normal gastric mucosa in the same patients (21). Several mechanisms have been proposed for the infiltration and accumulation of Tregs within the tumor microenvironment. One possibility is the recruitment in response to chemokines (Figure 2). It was reported that hypoxic intraperitoneal tumors recruited CD4⁺CD25⁺Foxp3⁺ Tregs through induction of CCL28, known as mucosa-associated epithelial chemokine (22). In addition, ovarian tumor cells and tumor microenvironmental macrophages produced the monocyte derived chemokine CCL22. Monoclonal antibody to CCL22 significantly decreased Treg cells migration into tumors *in vivo* (23). The second possible mechanism is

the preferential Treg expansion. Several lines of evidence indicated that interleukin 2 (IL-2) is essential for Treg development and homeostasis (24–26) (Figure 2). The mice deficient in IL-2, or interleukin 2 receptor (IL-2R) were characterized by T cell lymphoproliferation and lethal autoimmunity, which resulted from the absence of functional Tregs (27, 28). Ahmadzadeh and Rosenberg reported that the expansion of CD4⁺CD25⁺Foxp3⁺ Tregs was observed following IL-2 treatment in patients with metastatic melanoma and renal cell cancer (29). Likewise, Wei et al. demonstrated that IL-2 administration induced the proliferation of Tregs in ovarian cancer patients (30). Another possible mechanism is a *de novo* differentiation. Tumor derived TGF-β has been shown to induce the Tregs from Foxp3⁻ T cells (Figure 2). The studies from Chen's group demonstrated that TGF-β and TCR costimulation induced Foxp3 expression in CD4⁺CD25⁻ naïve responder murine T cells *in vitro* (31). Moreover, TGF-β converted CD4⁺CD25⁺ cells inhibited expansion of antigen-specific naïve CD4⁺ T cells *in vivo* in an ovalbumin peptide TCR transgenic adoptive transfer model (31). Furthermore, induction of CD4⁺CD25⁺Foxp3⁺ Tregs in a murine model of pancreas cancer was blocked with anti-TGF-β antibody treatment (32).

The crucial role of Tregs in tumor immunity is supported in animal models and clinical studies. Depletion of CD4⁺CD25⁺ cells with anti-CD25 antibody treatment in a murine model of melanoma resulted in the tumor growth suppression (9). Likewise, Linehan's group showed that depletion of CD4⁺CD25⁺ cells with anti-CD25 antibody alone or in combination with a whole tumor cell vaccine promoted a tumor-specific immune response with enzyme-linked immunospot assay analysis in pancreas cancer-bearing mice (33). They also demonstrated that Treg depletion and vaccination delayed tumor growth and prolonged host survival compared with untreated mice (33). CD8⁺ T cell-mediated adoptive cell therapy induced the regression of established melanoma in mice, but only when fractionated CD4⁺CD25⁻ T cells were transferred together with the CD8⁺ T cells. On the other hand, a co-transfer of unfractionated CD4⁺T cells (which would still contain Tregs) did not result in tumor regression (34). Administration of multi-peptide vaccine (hTERT/survivin) with anti-CD25 monoclonal antibody (mAb), Daclizumab, in patients with metastatic breast cancer patients led to the significant reduction of CD25⁺Foxp3⁺ Tregs in peripheral blood (35). Furthermore, effective generation of cytotoxic T lymphocytes specific for TERT and surviving antigens was demonstrated in these breast cancer patients (35). The studies from Dannull et al. used the recombinant IL-2 diphtheria toxin conjugate DAB₃₈₉IL-2, a targeted immunotoxin compound, for depletion of Tregs followed by vaccination with tumor RNA-transfected dendritic cells in metastatic renal cell carcinoma patients. A 7.9-fold median increase of tumor-specific CD8⁺ T cells was detected in the patients receiving combined treatments compared to a 2.7-fold median increase of tumor-specific CD8⁺ T cells in the patients receiving vaccination alone (36). Robbins's team has reported that the levels of peripheral reconstituting CD4⁺Foxp3⁺ Tregs in melanoma patients receiving tumor-infiltrating lymphocytes therapy were negatively associated with clinical responses in four clinical trials, which supported the notion that endogenous CD4⁺ Tregs plays a negative role in cancer immunotherapy (37).

4. Mechanism of Tregs-Mediated Immunosuppression

The precise suppressive mechanisms of Tregs in the context of tumor immunity are not exclusively defined. *In vitro* and *in vivo* studies of Treg cell function indicated that Tregs might use multiple mechanisms, which target various immune cells including the effector T cells, natural killer cells and dendritic cells (Figure 3).

4.1 Influence of Tregs on effector T cells

Many groups have demonstrated that CD4⁺CD25⁺ T cells potently suppress proliferation of other CD4⁺ and CD8⁺ T cells when Tregs and responder cells were co-cultured and stimulated with specific antigen or anti-CD3 mAb (38, 39). Some studies have shown that Tregs can kill effector T cells directly in culture through the release of granzyme B and perforin (40–42). In addition, Tregs can alter the differentiation of other T cells (43–45). Jonuleit et al. found that coculture of human CD4⁺CD25⁺ Tregs and CD4⁺CD25⁻ T cells not only suppressed the proliferation of conventional CD4⁺ T cells but also induced suppressive activity in these CD4⁺ T cells, resulting in the development of additional CD4⁺ suppressor T cells *in vitro*.

4.2 Modification of Antigen Presenting Cells by Treg Cells

Cederbom et al. has reported that CD4⁺CD25⁺ Tregs down-regulated the expression of the co-stimulatory molecules CD80 and CD86 on dendritic cells (46). In addition, several studies showed that Treg cells can stimulate antigen presenting cells to upregulate the activity of indoleamine 2,3-dioxygenase (IDO), which is a potent immunosuppressive enzyme that promotes peripheral immune tolerance by inhibiting T-cell activation and proliferation (47–49). On the other hand, Chung and colleagues found that mature human monocyte-derived dendritic cells expanded Tregs by an IDO-dependent mechanism (50). These observations indicated that there is a two-way communication between Tregs and dendritic cells.

4.3 Inhibition of Natural Killer (NK) Cell Function by Treg Cells

Ghiringhello et al. demonstrated that human Tregs directly inhibited NK cell functions and down-regulated NKG2D receptors on the NK cell surface (51). They also provided the evidence that human NK cell-mediated tumor recognition could be restored by depletion of Treg cells from tumor infiltrating lymphocytes (51). It was reported that *in vitro* NK cell proliferation and cytotoxicity towards tumor targets were inhibited by Tregs (52). Barao and colleagues demonstrated that NK cell-mediated bone marrow cell rejection was significantly augmented with prior Treg depletion of the recipient mice (53).

5. Tregs in Human Gynecological Cancer

The contributions of Tregs to the tolerogenic tumor microenvironment in the human gynecological cancer especially in the context of cervical cancer, vulvar cancer, and ovarian cancer are evaluated in this review. Such acquired body of knowledge would be essential for the development of effective immunotherapeutic strategies against human gynecological cancer.

5.1 Tregs in Human Cervical Cancer

Cervical cancer is the third most common cancer among women worldwide (54). An estimated 12,820 case of cervical cancer will be diagnosed and an estimated 4,210 deaths will occur in the US during 2017 (55). Persistent infection with high-risk human papillomavirus (HPV) including HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, 82 has been shown to be an important risk factor for the development of cervical cancer and its precursor lesions termed cervical intraepithelial neoplasia (CIN) (56). Of the high-risk HPV types, HPV type 16 is the most common types in malignant lesions, responsible for over 50% of invasive cervical cancer (57). Five-year survival rates for the patients diagnosed with localized, regional and distant-stage disease of cervical cancer are 91%, 57%, 17% respectively (55). Various investigations have indicated that development of HPV-induced cervical cancer is associated with the failure to induce the HPV specific type1 T-helper and cytotoxic T lymphocyte responses (58–61). Furthermore, several studies have identified the immunosuppressive microenvironment established during HPV associated cervical carcinogenesis (62–66). Multiple types of immunosuppressive cells including tumor-associated macrophage (TAM), regulatory dendritic cells, Tregs, are recruited and activated at the tumor sites (64, 67). Of note, accumulating data demonstrated that increased levels of Tregs were present at the cervical tumor site and in the lymph nodes and peripheral blood of patients with CIN or cervical cancer (65, 68–70). Characterization of Tregs using antibodies to Foxp3 was performed in six groups including HPV-positive cervicitis, HPV-negative cervicitis, CIN III, CIN II, CIN I, and squamous cell carcinoma (SCC) (68). Foxp3 positive cells were detected in all invasive tumors of SCC (30 cases) compared to only 12 of 30 cases in the CIN III group. They were detected in 5 of 11 cases in the patients of CIN II group, 4 of 10 cases in the CIN I group, 1 of 30 cases in the HPV positive cervicitis patients, and none of 7 HPV negative cervicitis patients (68). Moreover, the ratio of CD4⁺ T-cells to Foxp3 positive cells and that of CD8⁺ T-cells to Foxp3 positive cells were significantly reduced in the SCC group (11 ± 8 cells/mm² and 11 ± 8 cells/mm² respectively) compared to the CIN III group (43 ± 29 cells/mm² and 47 ± 25 cells/mm² respectively) with immunostaining analysis (68). Van der Burg and colleagues isolated HPV-specific CD4⁺ Tregs from lymph node biopsies of cervical cancer patients, which has been shown to suppress proliferation and cytokine interferon gamma (IFN- γ) and IL-2 production by responder T cells (71). In addition, Fattorossi's group examined the immune cell populations in metastatic tumor draining lymph nodes (mTDLN) and metastatic free tumor draining lymph nodes (mfTDLN), and discovered that CD4⁺Foxp3⁺ Tregs were more significantly abundant in mTDLN than mfTDLN (62). Moreover, Jordanova and colleagues showed that a high number of intraepithelial Tregs and a low CD8⁺ T-cell/Treg ratio were associated with worse survival in 115 cases of cervical cancer (72). CD8⁺ T-cell/Treg ratio was demonstrated to be the only single variable independent prognostic factor by multivariate statistical analysis in this study (72). Taken all together, cumulative evidence indicated that Treg may suppress the immune control of cervical neoplasia. Daemen's group showed that *in vitro* depletion of CD25⁺ Tregs from HPV16-positive cervical cancer patients led to the increased IFN- γ T cell responses against HPV16 E6 and E7 peptides (73). The studies from Cichon's research team demonstrated that inactivation of Tregs by agonistic anti-glucocorticoid-induced tumor necrosis factor receptor family-related protein (GITR) antibodies induced strong intra-tumoral invasion of CD8⁺ T cells and complete tumor

eradication in 70% of treated animals in a murine model of cervical cancer (70). Several therapeutic vaccines applying peptide or protein-based, vector-based, and cell-based strategies have been developed to treat patients with premalignant cervical and cervical cancers (74–83). A Phase I clinical trial with a human HPV therapeutic vaccine PepCan, which consists of four current good-manufacturing production-grade peptides covering the HPV16 E6 protein and *Candida* skin test reagent as a novel adjuvant, was evaluated in 34 women with cervical intraepithelial neoplasia CIN2/3 in our group. The observed overall histological response was 45% (14 of 31 patients who completed the study). Noticeably, pre-vaccination regulatory T cell levels were significantly lower in histological responders compared to non-responders ($p = 0.03$) (82, 83). Ferrara and colleagues reported that dendritic cell-based tumor vaccines pulsed with recombinant HPV16 E7 or HPV18 E7 oncoprotein were administered to 15 stage IV cervical cancer patients (76). Induction of IFN- γ secreting T-cell response was found in 3 out of 11 evaluated patients. However, no objective clinical response was observed in this study (76). Patients with HPV16-positive advanced or recurrent cervical cancer were vaccinated with an HPV16 synthetic long peptide vaccine consisting of the HPV16 E6 and E7 oncoproteins in Montanide adjuvant (79). The 9 out of the 11 vaccinated patients have shown the vaccine-induced HPV16-specific IFN- γ associated immune responses (79). However, no tumor regression was observed among the vaccinated patient (79). Also, compared to a cohort group of non-vaccinated patients, the median survival time among the vaccinated patients was not significantly different (8.5 ± 9.4 months in vaccinated group vs. 11.0 ± 7.7 months in matched cohort group, $p = 0.59$) (79). The same group also has shown that HPV16 synthetic long peptide vaccine induced HPV16-specific CD4 and CD8 T-cell responses in all six postoperative HPV16 positive cervical cancer patients (78). Expansion of CD4⁺CD25⁺Foxp3⁻ type 1 cytokine IFN- γ producing T cells as well as CD4⁺CD25⁺Foxp3⁺ T-cell population was observed in vaccinated patients (78). The two patients who displayed the local recurrence after vaccination had mounted the similar magnitude of percentage of HPV16-specific CD4⁺CD25⁺Foxp3⁻ T-cell subset and CD4⁺CD25⁺Foxp3⁺ T-cell subset. However, the other evaluable three patients who had no sign of recurrence during the time of follow-up had 3.9- to 11.4 -fold higher of percentage of HPV16-specific CD4⁺CD25⁺Foxp3⁻ subset than that of CD4⁺CD25⁺Foxp3⁺ T-cell subset (78). In the study of Stevanovic et al., nine patients with metastatic cervical cancer followed by chemotherapy previously were treated with tumor-infiltrating T cells selected for reactivity against HPV E6 and E7 proteins (84). Two of nine patients attained complete and one patient received partial response (84). This encouraging report indicated that properly activated T cells in adoptive T-cell therapy can produce tumor regression in patients with advanced cervical tumor. It is also noteworthy that combination of chemotherapy with adoptive T-cell therapy in this clinical trial might have a synergistic effect since several chemotherapy reagents have been shown to modulate the tumor microenvironment such as by eliminating Tregs or inducing the macrophage chemoattractant protein-1 (85–87). In the past, various immunotherapy clinical trials showed little clinical benefits especially in advanced cervical cancer patients. More recently, encouraging results are emerging using strategies to overcome immunosuppressive mechanisms to improve applicability of immunotherapy.

5.2 Tregs in Vulvar Cancer

Similar to cervical cancer, persistent infection with high risk types HPV including HPV16 are associated with vulvar cancers, which constitute 5.6% of all gynecologic cancers (88, 89). The incidence of vulvar intraepithelial neoplasia (VIN), a premalignant condition, which is increasing with 60–75% occurring in women under age of 50 (90–92). An estimated 6,020 of vulvar cancer cases will be diagnosed and an estimated 1,150 deaths will occur in the US during 2017 (55). The risk of progression from VIN to invasive cancer is from 3.8% to 9% (93, 94). Recurrence is a particularly problematic feature of vulvar cancer cases (95). Van Esch et al. reported that the usual-type vulvar intraepithelial neoplasia (uVIN) lesions, the most common VIN type lesions, were infiltrated by high numbers of Tregs (96, 97). They also found that a low CD8⁺TIM3⁺ T cells infiltration combined with higher infiltration of Tregs was negatively associated with the recurrence in uVIN (96). Importantly, compared to that in the uVIN tissues, the ratio of Treg/ CD8⁺TIM3⁺ T-cell in vulvar carcinoma tissues progressively increased (96). Vaccination of a synthetic long-peptide against the HPV-16 oncoproteins E6 and E7 in women with HPV-16 positive, grade 3 vulvar intraepithelial neoplasia displayed a 47% (9 of 19 patients) complete regression (CR)(98, 99). Compared to non- or partial responders, patients with CR mounted higher ratio of HPV16-specific effector T cells to HPV16-specific CD4⁺CD25⁺Foxp3⁺ Tregs. A combination of imiquimod, an immune response modifier, and HPV therapeutic vaccine comprising a HPV16 E6E7L2 fusion protein was given in 19 women with VIN grads 2 and 3 in a phase II clinical trial conducted by Daayana et al. (100). The effects of Imiquimod are mediated through agonistic activity towards toll-like receptors (TLR) 7 and 8, leading to activation of antigen-presenting cells (101). Complete regression of VIN was observed in 32% (6 out of 19 patients) in this study. Significantly increased local infiltration of CD8 and CD4 T cells was observed in responders, but an increased density of Tregs was identified in non-responders (100). The studies from these promising trials suggested that in the setting of premalignant disease, therapeutic strategy could potentially reach clinical efficiency through Treg modulation.

5.3 Tregs in Ovarian Cancer

Ovarian cancer accounts for 5% death among the women, causing more death than any other gynecological cancer. An estimated 22,440 ovarian cancer cases will be diagnosed and an estimated 14,080 deaths will occur in the US during 2017 (55). The 5-year relative survival rate for ovarian cancer is about 46% (55). Ovarian cancer is usually diagnosed in advanced stages due to the lack of obvious symptoms in the patients and effective screening methods. Current treatment includes debulking and chemotherapy with paclitaxel and platinum agents. In spite of the significant advances in surgery and chemotherapy, recurrence still occurs in about 70% of the patients who become refractory to further chemotherapies (102, 103). It has been shown that clinical outcome and five-year survival rate in patients are positively associated with the number of CD3⁺ tumor-infiltrating cytotoxic T lymphocytes (104, 105), which suggested that host immunity plays an important role in the course of ovarian cancer. Instead of being targeted for immune destruction, ovarian cancer has the ability to escape the immune system by creating a highly suppressive environment in the peritoneal cavity. Tregs, tolerance-inducing plasmacytoid dendritic cells (PDCs), B7-H4⁺ macrophage, immune-suppressive cytokines such as interleukin-10 (IL-10) and TGF- β are present in the ovarian

cancer environment (23, 106–109), which indicated that multiple cellular and molecular components created the immune suppressive network in ovarian cancer. High numbers of PDCs were found in malignant ascites of ovarian cancer patients (107). Tumor-associated PDCs induced angiogenesis *in vivo* through production of tumor necrosis factor α and interleukin 8. Kryczek et al. reported that ovarian tumor macrophages expressed high level of B7-H4 molecules, a negative regulator of T cell responses *in vitro* by inhibiting T cell proliferation, cell cycle progression, and cytokine production (108). They also demonstrated that tumor environmental interleukin 6 (IL-6) and IL-10 induced macrophage B7-H4 expression (108). Curiel et al. observed significant accumulation of CD4⁺CD25⁺Foxp3⁺ Tregs in malignant ascites and tumor tissues from 104 individuals with untreated ovarian cancer patients whereas CD4⁺CD25⁺Foxp3⁺ Tregs were undetectable in normal ovarian tissues without cancer (23). They demonstrated that accumulation of tumor Tregs predicts poor survival in individuals with ovarian cancer (23). In addition, Wolf and colleagues showed that high Foxp3 expression from 99 ovarian cancer patients was associated with poor prognosis in terms of overall survival ($p = 0.0034$) and progression-free survival ($p = 0.0041$) (110). Studies from Sata et al. reported that CD8⁺ tumor infiltrating lymphocytes (TILs) and a high CD8⁺ TILs/Tregs ratio were associated with favorable prognosis in ovarian cancer (111). Curiel et al. reported that tumor cells and tumor macrophages produced the chemokine CCL22, which mediated Tregs trafficking to tumor (23). Interestingly, they also found that tumor Tregs triggered macrophage to produce high levels of IL-10, which was responsible for B7-H4 expression (109, 112). The data from these studies implied that immunosuppressive network mechanisms might be established in the ovarian cancer. Successful ovarian cancer vaccine therapy might require the effective blockade of multiple immune-tolerance mechanisms. Several immunotherapy approaches have been used in ovarian cancer including therapeutic vaccines, monoclonal antibodies, checkpoint inhibitors and adoptive T cell transfer (113–118). Most of these therapies are still in early-phase testing. Odunsi et al. conducted a phase I clinical trial immunization with an NY-ESO-2 peptide in 18 ovarian patients (114). NY-ESO-1 is one of the most spontaneously immunogenic tumor antigens in testis and ovary (119). They have demonstrated that tumor-reactive CD4⁺CD8⁺ T cell responses were detected in ovarian cancer patients. However, clinical benefit afforded by vaccination has been marginal (114). A phase II trial using anti-PD-1 monoclonal antibody, Nivolumab, in 20 patients with platinum-resistant ovarian cancer showed encouraging results (116). Programmed cell death-1 (PD-1), an immune checkpoint receptor expressed by T cells, binds to two PD-1 ligands PD-L1 and PD-L2, and suppresses antigen-specific cancer immune reaction (120, 121). PD-L1 expression in tumor cells is associated with poor prognosis in ovarian cancer (104) and PD-L1 enables immune evasion during peritoneal dissemination by inhibition of cytotoxic T-lymphocyte function (122). The overall response in this trial was 15% and the disease control rate was 45% (116).

Clinical efficacy of immunotherapy may be enhanced by attempting to reduce immunosuppressive mediators such as Tregs. Certain chemotherapy regimens such as low dose of cyclophosphamide has been shown to reduce the number and function of Tregs that resulted in the increased immune response (123–125). For example, low-dose (300 mg/m²) cyclophosphamide treatment has yielded enhanced immunological and clinical responses when delivered in conjunction with hapten-modified melanoma vaccines and with

THERATOPE STn-KLH vaccination in breast cancer patients (126, 127). A combinational approach of a new dendritic cell vaccine for recurrent ovarian cancer in combination with antiangiogenesis therapy and metronomic cyclophosphamide was reported and awaited for future evaluation (87).

Concluding Remarks

During the past decade, remarkable progress has been made in understanding the interaction between the immune system and cancer. It is now appreciated that the immunological response against cancer is a critical balance between immune-activating and immune-suppressing mechanisms. The current wealth of information in the studies of tumor microenvironment in patients from cervical cancer, vulvar cancer and ovarian cancer indicated that Tregs are significant contributors to tumor-associated immune suppression. The knowledges in the functional studies of Tregs in each specific gynecological cancer type may provide new treatment strategies to effectively manipulate Tregs through methods such as depletion, blocking trafficking, and alleviating suppressive mechanism. It would be of interest to examine cancer therapy-induced changes on elimination or activation of Tregs in tissues and peripheral circulation of cancer patients. A combinational cancer vaccine combined with Tregs modulation would be a promising approach to attain an effective antitumor responses.

Acknowledgments

This study was funded by National Institutes of Health grants RO1 CA143130 and P50 CA136393.

References

1. Radoja S, Rao TD, Hillman D, Frey AB. 2000; Mice Bearing Late-Stage Tumors Have Normal Functional Systemic T Cell Responses In Vitro and In Vivo. *J Immunol.* 164:2619–2628. [PubMed: 10679101]
2. Willimsky G, Blankenstein T. 2005; Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. *Nature.* 437:141–146. [PubMed: 16136144]
3. Gershon RK, Kondo K. 1971; Infectious immunological tolerance. *Immunology.* 21:903–914. [PubMed: 4943147]
4. Fujimoto S, Greene MI, Sehon AH, Fujimoto SHI, Mark Igreene, Sehon AH. 1976; Regulation of the Immune Response to Tumor Antigens. *J Immunol.* 116:791–799. [PubMed: 1082894]
5. Hoon DS, Bowker RJ, Cochran AJ. 1987; Suppressor cell activity in melanoma-draining lymph nodes. *Cancer Res.* 47:1529–1533. [PubMed: 2949828]
6. Berendt MJ, North RJ. 1980; T-Cell-Mediated Suppression of Anti-tumor Immunity. *J Exp Med.* 151:69–80. [PubMed: 6444236]
7. Chakaraborty NTD. 1990; Autologous melanoma-induced activation of regulatory T cells that suppress cytotoxic response. *J Immunol.* 145:2359–2364. [PubMed: 1975829]
8. Sakaguchi S, Sakaguchi N. 1995; Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). *J Immunol.* 155:1151–1164. [PubMed: 7636184]
9. Shimizu J, Yamazaki S, Sakaguchi S. 1999; Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. *J Immunol.* 163:5211–5218. [PubMed: 10553041]
10. Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E. 1999; Tumor Rejection by in Vivo Administration of Anti-CD25 (Interleukin-2 Receptor α) Monoclonal Antibody. *Cancer Reserch.* 59:3128–3133.

11. Hsieh C-S, Lee H-M, Lio C-WJ. 2012; Selection of regulatory T cells in the thymus. *Nat Rev Immunol.* 12:157–167. [PubMed: 22322317]
12. Jordan MS, Boesteanu A, Reed aJ, Petrone aL, Hohenbeck aE, Lerman Ma, Najj A, Caton aJ. 2001; Thymic selection of CD4+CD25+ regulatory T cells induced by an agonist self-peptide. *Nat Immunol.* 2:301–306. [PubMed: 11276200]
13. Lee, HM, Bautista, JL, Hsieh, CS. *Advances in Immunology.* 1. Elsevier Inc; 2011. Thymic and Peripheral Differentiation of Regulatory T Cells; 25–71.
14. Shohei, Hori; Takashi Nomura, SS. 2003; Control of Regulatory T Cell Development by the Transcription Factor Foxp3. *Science (80-).* 299:1057–1061.
15. Zhou G, Levitsky HI. 2007; Natural Regulatory T Cells and De Novo-Induced Regulatory T Cells Contribute Independently to Tumor-Specific Tolerance. *J Immunol.* 178:2155–2162. [PubMed: 17277120]
16. Levings MK, Roncarolo MG. 2000; T-regulatory 1 cells: a novel subset of CD4 T cells with immunoregulatory properties. *J Allergy Clin Immunol.* 106:S109–S112. [PubMed: 10887343]
17. Levings MK, Sangregorio R, Galbiati F, Squadrone S, de Waal Malefyt R, Roncarolo MG. 2001; IFN-alpha and IL-10 induce the differentiation of human type 1 T regulatory cells. *J Immunol.* 166:5530–5539. [PubMed: 11313392]
18. Weiner HL. 2001; Oral tolerance: Immune mechanisms and the generation of Th3-type TGF-beta-secreting regulatory cells. *Microbes Infect.* 3:947–954. [PubMed: 11564443]
19. Woo EY, Chu CS, Goletz TJ, Schlienger K, Yeh H, Coukos G, Rubin SC, Kaiser LR, June CH. 2001; Regulatory CD4(+)-CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. *Cancer Res.* 61:4766–4772. [PubMed: 11406550]
20. Ormandy LA, Hillemann T, Wedemeyer H, Manns MP, Greten TF, Korangy F. 2005; Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. *Cancer Res.* 65:2457–2464. [PubMed: 15781662]
21. Mizukami Y, Kono K, Kawaguchi Y, Akaike H, Kamimura K, Sugai H, Fujii H. 2008; CCL17 and CCL22 chemokines within tumor microenvironment are related to accumulation of Foxp3+ regulatory T cells in gastric cancer. *Int J Cancer.* 122:2286–2293. [PubMed: 18224687]
22. Facciabene A, Peng X, Hagemann IS, Balint K, Barchetti A, Wang L-P, Gimotty PA, Gilks CB, Lal P, Zhang L, Coukos G. 2011; Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells. *Nature.* 475:226–230. [PubMed: 21753853]
23. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W. 2004; Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. *Nat Med.* 10:942–949. [PubMed: 15322536]
24. Almeida ARM, Legrand N, Papiernik M, Freitas AA. 2002; Homeostasis of Peripheral CD4+ T Cells: IL-2R{alpha} and IL-2 Shape a Population of Regulatory Cells That Controls CD4+ T Cell Numbers. *J Immunol.* 169:4850–4860. [PubMed: 12391195]
25. Furtado GC, Curotto de Lafaille MA, Kutchukhidze N, Lafaille JJ. 2002; Interleukin 2 signaling is required for CD4(+) regulatory T cell function. *J Exp Med.* 196:851–857. [PubMed: 12235217]
26. Malek TR, Yu A, Vincek V, Scibelli P, Kong L. 2002; CD4 Regulatory T Cells Prevent Lethal Autoimmunity in IL-2Rβ-Deficient Mice. *Immunity.* 17:167–178. [PubMed: 12196288]
27. Willerford DM, Chen J, Ferry JA, Davidson L, Ma A, Alt FW. 1995; Interleukin-2 receptor alpha chain regulates the size and content of the peripheral lymphoid compartment. *Immunity.* 3:521–530. [PubMed: 7584142]
28. Sadlack B, Lohler J, Schorle H, Klebb G, Haber H, Sickel E, Noelle RJ, Horak I. 1995; Generalized autoimmune disease in interleukin-2-deficient mice is triggered by an uncontrolled activation and proliferation of CD4+ T cells. *Eur J Immunol.* 25:3053–3059. [PubMed: 7489743]
29. Ahmadzadeh M, Rosenberg Sa. 2005; IL-2 administration increases CD4+CD25hi Foxp3+ regulatory T cells in cancer patients. *Blood.* 107:2409–2414. [PubMed: 16304057]
30. Wei S, Kryczek I, Edwards RP, Zou L, Szeliga W, Banerjee M, Cost M, Cheng P, Chang A, Redman B, Herberman RB, Zou W. 2007; Interleukin-2 administration alters the CD4+FOXP3+ T-

- cell pool and tumor trafficking in patients with ovarian carcinoma. *Cancer Res.* 67:7487–7494. [PubMed: 17671219]
31. Chen W, Jin W, Hardegen N, Lei K, Li L, Marinos N, McGrady G, Wahl SM. 2003; Conversion of peripheral CD4+ CD25– naive T cells to CD4+ CD25+ regulatory T cells by TGF- β induction of transcription factor Foxp3. *J Exp Med.* 198:1875–1886. [PubMed: 14676299]
 32. Moo Young, Tricia A; LarsonLDC, et al. Tumor derived TGF-beta conversion of CD4+Foxp3+ regulatory T cells in a murine model of pancreas cancer. *J Immunother.* 2009; 32(1):12–21. [PubMed: 19307989]
 33. Viehl CT, Moore TT, Liyanage UK, Frey DM, Ehlers JP, Eberlein TJ, Goedegebuure PS, Linehan DC. 2006; Depletion of CD4+CD25+ regulatory T cells promotes a tumor-specific immune response in pancreas cancer-bearing mice. *Ann Surg Oncol.* 13:1252–1258. [PubMed: 16952047]
 34. Antony PA, Piccirillo CA, Akpinarli A, Finkelstein SE, Speiss PJ, Surman DR, Palmer DC, Chan C-C, Klebanoff CA, Overwijk WW, Rosenberg SA, Restifo NP. 2005; CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. *J Immunol.* 174:2591–2601. [PubMed: 15728465]
 35. Rech AJ, Vonderheide RH. 2009; Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells. *Ann N Y Acad Sci.* 1174:99–106. [PubMed: 19769742]
 36. Dannull J, Su Z, Rizzieri D, Yang BK, Coleman D, Yancey D, Zhang A, Dahm P, Chao N, Gilboa E, Vieweg J. 2005; Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. *J Clin Invest.* 115:3623–3633. [PubMed: 16308572]
 37. Yao X, Ahmadzadeh M, Lu Y-C, Liewehr DJ, Dudley ME, Liu F, Schrumpp DS, Steinberg SM, Rosenberg SA, Robbins PF. 2012; Levels of peripheral CD4 +FoxP3 + regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer. *Blood.* 119:5688–5696. [PubMed: 22555974]
 38. Thornton AM, Shevach EM. 1998; CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. *J Exp Med.* 188:287–296. [PubMed: 9670041]
 39. Dieckmann D, Plottner H, Berchtold S, Berger T, Schuler G. 2001; Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood. *J Exp Med.* 193:1303–1310. [PubMed: 11390437]
 40. Gondek DC, Lu L-F, Quezada SA, Sakaguchi S, Noelle RJ. 2005; Cutting Edge: Contact-Mediated Suppression by CD4+CD25+ Regulatory Cells Involves a Granzyme B-Dependent, Perforin-Independent Mechanism. *J Immunol.* 174:1783–1786. [PubMed: 15699103]
 41. Cao X, Cai SF, Fehniger TA, Song J, Collins LI, Piwnicka-Worms DR, Ley TJ. 2007; Granzyme B and Perforin Are Important for Regulatory T Cell-Mediated Suppression of Tumor Clearance. *Immunity.* 27:635–646. [PubMed: 17919943]
 42. Grossman WJ, Verbsky JW, Barchet W, Colonna M, Atkinson JP, Ley TJ. 2004; Human T regulatory cells can use the perforin pathway to cause autologous target cell death. *Immunity.* 21:589–601. [PubMed: 15485635]
 43. Jonuleit H, Schmitt E, Kakirman H, Stassen M, Knop J, Enk AH. 2002; Infectious Tolerance. *J Exp Med.* 196:255–260. [PubMed: 12119350]
 44. Dieckmann D, Bruett CH, Ploettner H, Lutz MB, Schuler G. 2002; Human CD4(+)CD25(+) regulatory, contact-dependent T cells induce interleukin 10-producing, contact-independent type 1-like regulatory T cells. *J Exp Med.* 196:247–253. [PubMed: 12119349]
 45. Kearley J, Barker JE, Robinson DS, Lloyd CM. 2005; Resolution of airway inflammation and hyperreactivity after in vivo transfer of CD4+CD25+ regulatory T cells is interleukin 10 dependent. *J Exp Med.* 202:1539–1547. [PubMed: 16314435]
 46. Cederbom L, Hall H, Ivars F. 2000; CD4+CD25+ regulatory T cells down-regulate co-stimulatory molecules on antigen-presenting cells. *Eur J Immunol.* 30:1538–1543. [PubMed: 10898488]
 47. Puccetti P, Grohmann U. 2007; IDO and regulatory T cells: a role for reverse signalling and non-canonical NF-kappaB activation. *Nat Rev Immunol.* 7:817–823. [PubMed: 17767193]

48. Hwu P, Du MX, Lapointe R, Do M, Taylor MW, Young HA. 2000; Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. *J Immunol.* 164:3596–3599. [PubMed: 10725715]
49. Fallarino F, Grohmann U, Hwang KW, Orabona C, Vacca C, Bianchi R, Belladonna ML, Fioretti MC, Alegre M-L, Puccetti P. 2003; Modulation of tryptophan catabolism by regulatory T cells. *Nat Immunol.* 4:1206–1212. [PubMed: 14578884]
50. Chung, David J; Rossi, Marco; Romano, Emanuela; , et al. Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells. *Blood.* 2009; 114(3):555–563. [PubMed: 19465693]
51. Ghiringhelli F, Menard C, Terme M, Flament C, Taieb J, Chaput N, Puig PE, Novault S, Escudier B, Vivier E, Levesne A, Robert C, Blay J-Y, Bernard J, Caillat-Zucman S, Freitas A, Tursz T, Wagner-Ballon O, Capron C, Vainchenker W, Martin F, Zitvogel L. 2005; CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor- β -dependent manner. *J Exp Med.* 202:1075–1085. [PubMed: 16230475]
52. Zimmer J, Andr es E, Hentges F. 2008; NK cells and Treg cells: A fascinating dance cheek to cheek. *Eur J Immunol.* 38:2942–2945. [PubMed: 18979513]
53. Barao I, Hanash AM, Hallett W, Welniak LA, Sun K, Redelman D, Blazar BR, Levy RB, Murphy WJ. 2006; Suppression of natural killer cell-mediated bone marrow cell rejection by CD4+CD25+ regulatory T cells. *Proc Natl Acad Sci U S A.* 103:5460–5465. [PubMed: 16567639]
54. Jemal A, Bray F, Ferlay J. 2011; Global Cancer Statistics: 2011. *CA Cancer J Clin.* 61:69–90. [PubMed: 21296855]
55. Facts C. 2017Cancer Facts and Figures 2017. Am Cancer Soc.
56. Mu oz N, de Sanjos  S, Bosch FX, et al. Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical Cancer. *N Engl J. Med.* 2003; 348(6):518–527. [PubMed: 12571259]
57. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford GM. 2007; Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: A meta-analysis update. *Int J Cancer.* 121:621–632. [PubMed: 17405118]
58. De, Jong A; Van, Poelgeest MIE; Van Der, Hulst JM; , et al. Human Papillomavirus Type 16–Positive Cervical Cancer Is Associated with Impaired CD4 + T-Cell Immunity against Early Antigens E2 and E6. *Cancer Res.* 2004; 64(15):5449–5455. [PubMed: 15289354]
59. De Vos Van Steenwijk PJ, Piersma SJ, Welters MJP, Van Der Hulst JM, Fleuren G, Hellebrekers BWJ, Kenter GG, Van Der Burg SH. 2008; Surgery followed by persistence of high-grade squamous intraepithelial lesions is associated with the induction of a dysfunctional HPV16-specific T-Cell response. *Clin Cancer Res.* 14:7188–7195. [PubMed: 19010835]
60. Kim KH, Greenfield WW, Cannon MJ, Coleman HN, Spencer HJ, Nakagawa M. 2012; CD4+ T-cell response against human papillomavirus type 16 E6 protein is associated with a favorable clinical trend. *Cancer Immunol Immunother.* 61:63–70. [PubMed: 21842207]
61. Nakagawa M, Stites DP, Patel S, Farhat S, Scott M, Hills NK, Palefsky JM, Moscicki AB. 2000; Persistence of human papillomavirus type 16 infection is associated with lack of cytotoxic T lymphocyte response to the E6 antigens. *J Infect Dis.* 182:595–598. [PubMed: 10915094]
62. Battaglia A, Buzzonetti A, Baranello C, Ferrandina G, Martinelli E, Fanfani F, Scambia G, Fattorossi A. 2009; Metastatic tumour cells favour the generation of a tolerogenic milieu in tumour draining lymph node in patients with early cervical cancer. *Cancer Immunol Immunother.* 58:1363–1373. [PubMed: 19172271]
63. Kobayashi, a; Weinberg, V; Darragh, T; Smith-McCune, K. 2008; Evolving immunosuppressive microenvironment during human cervical carcinogenesis. *Mucosal Immunol.* 1:412–420. [PubMed: 19079205]
64. Heeren AM, Koster BD, Samuels S, Ferns DM, Chondronasiou D, Kenter GG, Jordanova ES, de Gruijl TD. 2015; High and interrelated rates of PD-L1+CD14+ antigen-presenting cells and regulatory T cells mark the microenvironment of metastatic lymph nodes from patients with cervical cancer. *Cancer Immunol Res.* 3:48–58. [PubMed: 25361854]

65. Fattorossi A, Battaglia A, Ferrandina G, Buzzonetti A, Legge F, Salutari V, Scambia G. 2004; Lymphocyte composition of tumor draining lymph nodes from cervical and endometrial cancer patients. *Gynecol Oncol.* 92:106–115. [PubMed: 14751146]
66. Piersma SJ. 2011; Immunosuppressive tumor microenvironment in cervical cancer patients. *Cancer Microenviron.* 4:361–375. [PubMed: 21626415]
67. Hammes LS, Tekmal RR, Naud P, Edelweiss MI, Kirma N, Valente PT, Syrjanen KJ, Cunha-Filho JS. 2007; Macrophages, inflammation and risk of cervical intraepithelial neoplasia (CIN) progression-Clinicopathological correlation. *Gynecol Oncol.* 105:157–165. [PubMed: 17229459]
68. Adurthi S, Krishna S, Mukherjee G, Bafna UD, Devi U, Jayshree RS. 2008; Regulatory T cells in a spectrum of HPV-induced cervical lesions: Cervicitis, cervical intraepithelial neoplasia and squamous cell carcinoma. *Am J Reprod Immunol.* 60:55–65. [PubMed: 18593438]
69. Molling JW, De Gruijl TD, Glim J, Moreno M, Rozendaal L, Meijer CJLM, Van Den Eertwegh AJM, Scheper RJ, Von Blomberg ME, Bontkes HJ. 2007; CD4+CD25hi regulatory T-cell frequency correlates with persistence of human papillomavirus type 16 and T helper cell responses in patients with cervical intraepithelial neoplasia. *Int J Cancer.* 121:1749–1755. [PubMed: 17582606]
70. Loddenkemper C, Hoffmann C, Stanke J, Nagorsen D, Baron U, Olek S, Huehn J, Ritz JP, Stein H, Kaufmann AM, Schneider A, Cichon G. 2009; Regulatory (FOXP3+) T cells as target for immune therapy of cervical intraepithelial neoplasia and cervical cancer. *Cancer Sci.* 100:1112–1117. [PubMed: 19514119]
71. Van Der Burg SH, Piersma SJ, De Jong A, Van Der Hulst JM, Kwappenberg KMC, Van Den Hende M, Welters MJP, Van Rood JJ, Fleuren GJ, Melief CJM, Kenter GG, Offringa R. 2007; Association of cervical cancer with the presence of CD4 regulatory T cells specific for human papillomavirus antigens. *Proc Natl Acad Sci U S A.* 104:12087–12092. [PubMed: 17615234]
72. Jordanova ES, Gorter A, Ayachi O, Prins F, Durrant LG, Kenter GG, Van Der Burg SH, Fleuren GJ. 2008; Human leukocyte antigen class I, MHC class I chain-related molecule A, and CD8+/regulatory T-cell ratio: Which variable determines survival of cervical cancer patients? *Clin Cancer Res.* 14:2028–2035. [PubMed: 18381941]
73. Visser J, Nijman HW, Hoogenboom BN, Jager P, Van Baarle D, Schuurin E, Abdulahad W, Miedema F, Van Der Zee AG, Daemen T. 2007; Frequencies and role of regulatory T cells in patients with (pre)malignant cervical neoplasia. *Clin Exp Immunol.* 150:199–209. [PubMed: 17937675]
74. Steller MA, Gurski KJ, Murakami M, Daniel RW, Shah KV, Celis E, Sette A, Trimble EL, Park RC, Marincola FM. 1998; Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7. *Clin Cancer Res.* 4:2103–2109. [PubMed: 9748126]
75. Maciag PC, Radulovic S, Rothman J. 2009; The first clinical use of a live-attenuated *Listeria monocytogenes* vaccine: A Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix. *Vaccine.* 27:3975–3983. [PubMed: 19389451]
76. Ferrara A, Nonn M, Sehr P, Schreckenberger C, Pawlita M, Dürst M, Schneider A, Kaufmann AM. 2003; Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients. *J Cancer Res Clin Oncol.* 129:521–530. [PubMed: 12898233]
77. Borysiewicz L, Fiander A, Nimako M, Man S, Wilkinson G, Westmoreland D, Evans A, Adams M, Stacey S, Boursnell M, Rutherford E, Hickling J, Inglis S. 1996; A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. *Lancet.* 347:1523–1527. [PubMed: 8684105]
78. Welters MJP, Kenter GG, Piersma SJ, Vloon APG, Lowik MJG, Berends-van der Meer DMA, Drijfhout JW, Valentijn ARPM, Wafelman AR, Oostendorp J, Fleuren GJ, Offringa R, Melief CJM, van der Burg SH. 2008; Induction of Tumor-Specific CD4+ and CD8+ T-Cell Immunity in Cervical Cancer Patients by a Human Papillomavirus Type 16 E6 and E7 Long Peptides Vaccine. *Clin Cancer Res.* 14:178–187. [PubMed: 18172269]
79. van Poelgeest MIE, Welters MJP, van Esch EMG, Stynenbosch LFM, Kerpershoek G, van Persijn van Meerten EL, van den Hende M, Löwik MJG, Berends-van der Meer DMA, Fathers LM, Valentijn ARPM, Oostendorp J, Fleuren GJ, Melief CJM, Kenter GG, van der Burg SH. 2013; HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or

- recurrent HPV16-induced gynecological carcinoma, a phase II trial. *J Transl Med.* 11:88. [PubMed: 23557172]
80. Frazer IH, Quinn M, Nicklin JL, Tan J, Perrin LC, Ng P, O'Connor VM, White O, Wendt N, Martin J, Crowley JM, Edwards SJ, McKenzie AW, Mitchell SV, Maher DW, Pearse MJ, Bassler RL. 2004; Phase I study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIXTM adjuvant in women with cervical intraepithelial neoplasia. *Vaccine.* 23:172–181. [PubMed: 15531034]
 81. Kaufmann A, Stern P, Rankin E, Sommer H, Nuessler V, Schneider A, Bauknecht T, Wagner U, Kroon K, Hickling J, Boswell C, Stacey S, Kitchener H, Gillard J, Wanders J. 2002; Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. *Clin Cancer Res.* 8:3676–3685. [PubMed: 12473576]
 82. Greenfield WW, Stratton SL, Myrick RS, Vaughn R, Donnalley LM, Coleman HN, Mercado M, Moerman-Herzog AM, Spencer HJ, Andrews-Collins NR, Hitt WC, Low GM, Manning NA, McKelvey SS, Smith D, Smith MV, Phillips AM, Quick CM, Jeffus SK, Hutchins LF, Nakagawa M. 2015; A phase I dose-escalation clinical trial of a peptide-based human papillomavirus therapeutic vaccine with Candida skin test reagent as a novel vaccine adjuvant for treating women with biopsy-proven cervical intraepithelial neoplasia 2/3. *Oncoimmunology.* 4:e1031439. [PubMed: 26451301]
 83. Coleman HN, Greenfield WW, Stratton SL, Vaughn R, Kieber A, Moerman-Herzog AM, Spencer HJ, Hitt WC, Quick CM, Hutchins LF, Mackintosh SG, Edmondson RD, Erickson SW, Nakagawa M. 2016; Human papillomavirus type 16 viral load is decreased following a therapeutic vaccination. *Cancer Immunol Immunother.* 65:563–573. [PubMed: 26980480]
 84. Stevanovic S, Draper LM, Langhan MM, Campbell TE, Kwong ML, Wunderlich JR, Dudley ME, Yang JC, Sherry RM, Kammula US, Restifo NP, Rosenberg SA, Hinrichs CS. 2015; Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. *J Clin Oncol.* 33:1543–1550. [PubMed: 25823737]
 85. Rettig L, Seidenberg S, Parvanova I, Samaras P, Knuth A, Pascolo S. 2011; Gemcitabine depletes regulatory T-cells in human and mice and enhances triggering of vaccine-specific cytotoxic T-cells. *Int J Cancer.* 129:832–838. [PubMed: 21710545]
 86. Getter MA, Bui-Nguyen TM, Rogers LM, Ramakrishnan S. 2010; Chemotherapy induces macrophage chemoattractant protein-1 production in ovarian cancer. *Int J Gynecol Cancer.* 20:918–925. [PubMed: 20683396]
 87. Kandalaf LE, Chiang CL, Tanyi J, Motz G, Balint K, Mick R, Coukos G. 2013; A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer. *J Transl Med.* 11:149. [PubMed: 23777306]
 88. Madeleine MM, Daling JR, Carter JJ, Wipf GC, Schwartz SM, McKnight B, Kurman RJ, Beckmann aM, Hagensee ME, Galloway Da. 1997; Cofactors with human papillomavirus in a population-based study of vulvar cancer. *J Natl Cancer Inst.* 89:1516–1523. [PubMed: 9337348]
 89. Siegel R, Miller K, Jemal A. 2017; Cancer statistics, 2017. *CA Cancer J Clin.* 67:7–30. [PubMed: 28055103]
 90. Joura EA, Losch A, Haider-Angeler MG, Breitenecker G, Leodolter S. 2000; Trends in vulvar neoplasia. Increasing incidence of vulvar intraepithelial neoplasia and squamous cell carcinoma of the vulva in young women. *J Reprod Med.* 45:613–615. [PubMed: 10986677]
 91. Judson PL, Habermann EB, Baxter NN, Durham SB, Virnig BA. 2006; Trends in the incidence of invasive and in situ vulvar carcinoma. *Obstet Gynecol.* 107:1018–1022. [PubMed: 16648405]
 92. Jones RW, Rowan DM, Stewart AW. 2005; Vulvar intraepithelial neoplasia: aspects of the natural history and outcome in 405 women. *Obstet Gynecol.* 106:1319–1326. [PubMed: 16319258]
 93. Jones, Ronald W; Frcog Frcs, RDM. 1994; Vulvar intraepithelial neoplasia III: A clinical study of the outcome in 113 cases with relation to the later development of invasive vulvar carcinoma. *Obstet Gynecol.* 84:741–745. [PubMed: 7936504]
 94. Van Seters M, Van Beurden M, De Craen AJM. 2005; Is the assumed natural history of vulvar intraepithelial neoplasia III based on enough evidence? A systematic review of 3322 published patients. *Gynecol Oncol.* 97:645–651. [PubMed: 15863172]

95. Wallbillich JJ, Rhodes HE, Milbourne AM, Munsell MF, Frumovitz M, Brown J, Trimble CL, Schmeler KM. 2012; Vulvar intraepithelial neoplasia (VIN 2/3): Comparing clinical outcomes and evaluating risk factors for recurrence. *Gynecol Oncol.* 127:312–315. [PubMed: 22867736]
96. Van Esch EMG, Van Poelgeest MIE, Kouwenberg S, Osse EM, Trimbos JBMZ, Fleuren GJ, Jordanova ES, Van Der Burg SH. 2015; Expression of coinhibitory receptors on T cells in the microenvironment of usual vulvar intraepithelial neoplasia is related to proinflammatory effector T cells and an increased recurrence-free survival. *Int J Cancer.* 136:E95–E106. [PubMed: 25220367]
97. Preti M. 2015; VIN usual type—from the past to the future. *Ecancermedalscience.* 9:531. [PubMed: 25987900]
98. Kenter GG, Welters MJP, Valentijn aRPM, Lowik MJG, Berends-van der Meer DMA, Vloon APG, Essahsah F, Fathers LM, Offringa R, Drijfhout JW, Wafelman AR, Oostendorp J, Fleuren GJ, van der Burg SH, Melief CJM. 2009; Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. *N Engl J Med.* 361:1838–1847. [PubMed: 19890126]
99. Welters MJP, Kenter GG, de Vos van Steenwijk PJ, Löwik MJG, Berends-van der Meer DMA, Essahsah F, Stynenbosch LFM, Vloon APG, Ramwadhoebe TH, Piersma SJ, van der Hulst JM, Valentijn ARPM, Fathers LM, Drijfhout JW, Franken KLMC, Oostendorp J, Fleuren GJ, Melief CJM, van der Burg SH. 2010; Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. *Proc Natl Acad Sci U S A.* 107:11895–11899. [PubMed: 20547850]
100. Daayana S, Elkord E, Winters U, Pawlita M, Roden R, Stern PL, Kitchener HC. 2010; Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulvar intraepithelial neoplasia. *Br J Cancer.* 102:1129–1136. [PubMed: 20234368]
101. Schön MP, Schön M. 2007; Imiquimod: Mode of action. *Br J Dermatol.* 157:8–13. [PubMed: 18067624]
102. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R, Mackey D. 2003; Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study. *J Clin Oncol.* 21:3194–3200. [PubMed: 12860964]
103. Winter WE, Maxwell GL, Tian C, Carlson JW, Ozols RF, Rose PG, Markman M, Armstrong DK, Muggia F, McGuire WP. 2007; Prognostic factors for stage III epithelial ovarian cancer: A Gynecologic Oncology Group study. *J Clin Oncol.* 25:3621–3627. [PubMed: 17704411]
104. Zhang L, Conejo-Garcia JJR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC, Coukos G. 2003; Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. *N Engl J Med.* 348:203–213. [PubMed: 12529460]
105. Hwang W-T, Adams SF, Tahirovic E, Hagemann IS, Coukos G. 2012; Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. *Gynecol Oncol.* 124:192–198. [PubMed: 22040834]
106. Wei S, Kryczek I, Zou L, Daniel B, Cheng P, Mottram P, Curiel T, Lange A, Zou W. 2005; Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma. *Cancer Res.* 65:5020–5026. [PubMed: 15958543]
107. Curiel TJ, Cheng P, Mottram P, Alvarez X, Moons L, Evdemon-hogan M, Wei S, Zou L, Kryczek I, Hoyle G, Lackner A, Carmeliet P, Zou W. 2004; Dendritic Cell Subsets Differentially Regulate Angiogenesis in Human Ovarian Cancer. *Cancer Res.* 64:5535–5538.
108. Kryczek I, Zou L, Rodriguez P, Zhu G, Wei S, Mottram P, Brumlik M, Cheng P, Curiel T, Myers L, Lackner A, Alvarez X, Ochoa A, Chen L, Zou W. 2006; B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. *J Exp Med.* 203:871–881. [PubMed: 16606666]
109. Kryczek I, Wei S, Zhu G, Myers L, Mottram P, Cheng P, Chen L, Coukos G, Zou W. 2007; Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. *Cancer Res.* 67:8900–8905. [PubMed: 17875732]
110. Wolf D, Wolf AM, Rumpold H, Fiegl H, Zeimet AG, Muller-Holzner E, Deibl M, Gastl G, Gunsilius E, Marth C. 2005; The expression of the regulatory T cell-specific forkhead box

- transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. *Clin Cancer Res.* 11:8326–8331. [PubMed: 16322292]
111. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, Jungbluth AA, Frosina D, Gnjatic S, Ambrosone C, Kepner J, Odunsi T, Ritter G, Lele S, Chen Y-T, Ohtani H, Old LJ, Odunsi K. 2005; Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. *Pnas.* 102:18538–18543. [PubMed: 16344461]
 112. Kryczek I, Wei S, Zou L, Zhu G, Mottram P, Xu H, Chen L, Zou W. 2006; Cutting Edge: Induction of B7-H4 on APCs through IL-10: Novel Suppressive Mode for Regulatory T Cells. *J Immunol.* 177:40–44. [PubMed: 16785496]
 113. Disis ML, Gooley TA, Rinn K, Davis D, Piepkorn M, Cheever MA, Knutson KL, Schiffman K. 2002; Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. *J Clin Oncol.* 20:2624–2632. [PubMed: 12039923]
 114. Odunsi K, Qian F, Matsuzaki J, Mhawech-Fauceglia P, Andrews C, Hoffman EW, Pan L, Ritter G, Vilella J, Thomas B, Rodabaugh K, Lele S, Shrikant P, Old LJ, Gnjatic S. 2007; Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. *Proc Natl Acad Sci U S A.* 104:12837–12842. [PubMed: 17652518]
 115. Reinartz S, Köhler S, Schlebusch H, Krista K, Giffels P, Renke K, Huober J, Möbus V, Kreienberg R, DuBois A, Sabbatini P, Wagner U. 2004; Vaccination of Patients with Advanced Ovarian Carcinoma with the Anti-Idiotypic ACA125: Immunological Response and Survival (Phase Ib/II). *Clin Cancer Res.* 10:1580–1587. [PubMed: 15014007]
 116. Hamanishi J, Mandai M, Ikeda T, Minami M, Kawaguchi A, Murayama T, Kanai M, Mori Y, Matsumoto S, Chikuma S, Matsumura N, Abiko K, Baba T, Yamaguchi K, Ueda A, Hosoe Y, Morita S, Yokode M, Shimizu A, Honjo T, Konishi I. 2015; Safety and antitumor activity of Anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. *J Clin Oncol.* 33:4015–4022. [PubMed: 26351349]
 117. Aoki Y, Takakuwa K, Kodama S, Tanaka K, Takahashi M, Tokunaga A, Takahashi T. 1991; Use of adoptive transfer of tumor-infiltrating lymphocytes alone or in combination with cisplatin-containing chemotherapy in patients with epithelial ovarian cancer. *Cancer Res.* 51:1934–1939. [PubMed: 2004379]
 118. Fujita K, Ikarashi H, Akiteru K. 1995; Prolonged disease-free period in patients with advanced epithelial ovarian cancer after adoptive transfer of tumor-infiltrating lymphocytes. *Clin Cancer Res.* 1:501–507. [PubMed: 9816009]
 119. Chen YT, Scanlan MJ, Sahin U, Türeci O, Gure AO, Tsang S, Williamson B, Stockert E, Pfreundschuh M, Old LJ. 1997; A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. *Proc Natl Acad Sci U S A.* 94:1914–1918. [PubMed: 9050879]
 120. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. 2008; PD-1 and Its Ligands in Tolerance and Immunity. *Annu Rev Immunol.* 26:677–704. [PubMed: 18173375]
 121. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. 2002; Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. *Proc Natl Acad Sci U S A.* 99:12293–12297. [PubMed: 12218188]
 122. Abiko K, Mandai M, Hamanishi J, Yoshioka Y, Matsumura N, Baba T, Yamaguchi K, Murakami R, Yamamoto A, Kharma B, Kosaka K, Konishi I. 2013; PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction. *Clin Cancer Res.* 19:1363–1374. [PubMed: 23340297]
 123. Ghiringhelli F, Larmonier N, Schmitt E, Parcellier A, Cathelin D, Garrido C, Chauffert B, Solary E, Bonnotte B, Martin F. 2004; CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. *Eur J Immunol.* 34:336–344. [PubMed: 14768038]
 124. Ikezawa Y, Nakazawa M, Tamura C, Takahashi K, Minami M, Ikezawa Z. 2005; Cyclophosphamide decreases the number, percentage and the function of CD25+ CD4+ regulatory T cells, which suppress induction of contact hypersensitivity. *J Dermatol Sci.* 39:105–112. [PubMed: 15899580]

125. Bass KK, Mastrangelo MJ. 1998; Immunopotential with low-dose cyclophosphamide in the active specific immunotherapy of cancer. *Cancer Immunol Immunother.* 47:1–12. [PubMed: 9755873]
126. Berd D, Sato T, Maguire HC, Kairys J, Mastrangelo MJ. 2004; Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine. *J Clin Oncol.* 22:403–415. [PubMed: 14691123]
127. MacLean GD, Miles DW, Rubens RD, Reddish MALB. 1996; Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide. *J Immunother Emphas Tumor Immunol.* 19:309–316.




Figure 1. Thymic and peripheral generation of Tregs. tTregs are selected by high-avidity interaction between T cell receptors and self-peptide-MHC class II complexes in the thymus. Peripheral Tregs develop outside the thymus under suboptimal antigen presentation. pTregs are derived from naïve CD4⁺ T cells. In addition, pTregs comprise two additional subsets Tr1 and Th3.




Figure 2. Mechanisms of infiltration and accumulation of Tregs in the tumor microenvironment: (1) Tregs are recruited to tumor from the periphery by chemokines e.g. CCL28 or CCL12; (2) Within the tumor microenvironment Tregs can be expanded by IL-2 administration; (3) Tumor derived TGF-β can convert naïve CD4⁺ T cells into Tregs.




Figure 3. Mechanisms of Tregs-mediated immunosuppression. Tregs promote tumor progression by (1) inhibition of effector T cell proliferation, lysis of effector T cells through release of granzyme B and perforin, or conversion of CD4⁺ T cells into Tregs; (2) interactions with DCs through downregulation of CD80/CD86 on DCs or upregulation of indoleamine 2,3-dioxygenase IDO in DCs; (3) inhibition of NK cell function through downregulation of NKG2D on NK cells or direct inhibition of NK proliferation and cytotoxicity.